LifeArc is a British life science medical research charity. It was established in 2000 as MRC Technology to translate the work of UK Medical Research Council (MRC) research scientists.Today, LifeArc provides intellectual property identification, protection and commercialisation, technology development, diagnostic development, early stage drug discovery and antibody humanization services for the MRC, academia, biotechnology and pharmaceutical organisations and charities, aiming to move promising medical research forward into viable and accessible patient treatments. Profits from LifeArc's activities are reinvested into further research.LifeArc uses funds from royalty payments to provide grants into rare disease research and allocates seed funding to UK companies.
Background: Motor neuron disease (MND) is a fatal neurodegenerative condition with significant clinical heterogeneity that is incompletely captured by existing phenotype classifications based on onset site. Electronic health records (EHRs) contain detailed symptom documentation in clinical narratives that may enable data-driven discovery of clinically meaningful patient subgroups. Methods: We developed a natural language processing (NLP) pipeline using MedCAT to extract symptoms from clinical notes of 2,361 people with a confirmed diagnosis of MND at a tertiary neurology center. MND cohort confirmation used three complementary methods: clinic attendance records, text-based diagnosis detection, and NLP extraction with negation detection. Extracted symptoms were filtered to Unified Medical Language System semantic type T184 (Sign or Symptom) with removal of negated concepts. Patients were clustered using latent class analysis on binary symptom profiles. Survival differences were assessed using Kaplan-Meier analysis, log-rank tests, and Cox proportional hazards regression. Results: From the first clinical notes, we identified four clusters of symptoms among 872 patients and 76 symptoms: Motor-Bulbar (n=373), Motor-Tremor (n=154), Sensory-Pain (n=222), and Motor-Respiratory (n=123). When extended to all clinical notes (n=2,065; 184 symptoms), these reorganized into three clusters: Autonomic-Respiratory (n=472), Nocturnal-Respiratory (n=338), and Classic Motor (n=1,255). Survival differences were significant across all clusters in both the first notes and all notes analyses (log-rank p < 0.001). Conclusions: NLP-based symptom extraction from EHRs identifies clinically meaningful MND subgroups that extend beyond traditional onset-site classifications. Autonomic-respiratory symptom burden is associated with poorer survival while a newly identified Sensory-Pain subtype with a better prognosis. These data-driven phenotypes may improve prognostication and inform targeted supportive care. ### Competing Interest Statement The authors have declared no competing interest. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The KERRI committee of King's College Hospital gave ethical approval for this work. The datasets used in your study had been de-identified prior to use in this study. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Clinical data cannot be shared due to patient confidentiality. EPSRC, EP/Y035216/1
Two-pore domain potassium (K2P) channels are novel analgesic drug targets with existing in vitro and in vivo validation, however genetic associations in large scale populations have not been widely reported. By examining two comprehensive genetic databases (UK Biobank & FinnGen) and 136 pain-related traits, we highlight that multiple pain-associated signals are present within 500 kb of K2P gene transcripts, with particularly strong evidence for KCNK5 (TASK-2) and headache-related traits. This data benchmarks remarkably well against gene targets already considered to be well validated pain targets (voltage-gated sodium and transient receptor potential channels) and is enhanced when examining populations regularly consuming analgesics who also report pain. This data supports a rationale for developing therapeutic strategies to modulate K2P function in patient populations experiencing pain.
Chronic respiratory diseases (CRDs) represent a major global health burden, with diagnosis frequently delayed by overlapping symptoms, limited access to testing and reliance on effort-dependent lung function measures. Earlier diagnosis in primary care remains a critical unmet need. We reviewed the current and emerging landscape of CRD diagnostics using a market intelligence database (GlobalData), focusing on technologies with potential to support early diagnosis and triage. The current diagnostic landscape is dominated by lung function testing, particularly spirometry. However, the development pipeline suggests a shift towards indirect approaches, including breath analysis and acoustic technologies. These emerging technologies offer the potential for more accessible, patient-centred diagnostics suited to primary care and other community settings. However, realising this potential will require robust validation and integration within clinical pathways. In addition, innovation remains concentrated on more prevalent CRDs with comparatively limited activity focused on rarer conditions. Addressing this imbalance will be critical to improving equity and reducing diagnostic delay for all individuals living with CRD. Co-ordinated action from innovators, funders and system decision-makers will be essential to accelerate the translation of the most promising solutions into clinical practice, while ensuring that the needs of those with rarer lung conditions are not overlooked.
The increasing prevalence of antimicrobial resistance is an important challenge that warrants new approaches to antibiotic development. Currently, all antibiotics inhibit biological processes. To explore whether activation of a biochemical pathway can elicit bactericidal effects we engineered variants of Mycobacterium tuberculosis ATP-phosphoribosyltransferase (ATP-PRT) that are resistant to allosteric inhibition by L-histidine, leading to supraphysiological activation of ATP-PRT and L-histidine overproduction. Upregulation of L-histidine biosynthesis significantly reduces the growth of M. tuberculosis in culture and causes a loss of fitness owing to nutrient and energy depletion. Moreover, the expression of allosteric variants in M. tuberculosis significantly reduced infections in human macrophages and in a mouse model of infection. Thus, metabolic activation represents a new mycobactericidal mechanism that could be applied to antimycobacterial drug discovery.
Abstract Background Geriatric syndromes (GS) are complex conditions that affect older adults and often require multidisciplinary assessment. Natural language processing (NLP) has emerged as a promising tool for extracting relevant clinical information from unstructured text in electronic health records (EHRs). However, the application of NLP in detecting and monitoring GS remains an evolving area of research. This systematic review explores the role of NLP in the identification and analysis of GS, examining its applications, methodologies, and effectiveness. Furthermore, this review discusses the existing challenges, limitations, and future directions to advance NLP applications in the GS research. Methods We conducted a systematic literature search across ten databases to identify studies that applied NLP to GS detection. Articles were screened using predefined inclusion and exclusion criteria, and relevant studies were evaluated for quality using PROBAST. Data were extracted on study characteristics, datasets, annotation processes, NLP approaches, performance metrics, population demographics, and clinical applications. A PRISMA flow diagram was used to illustrate the study selection process. Results A total of 65 studies were included, where the majority of the studies used traditional rule-based and machine learning approaches. Publicly available datasets were scarce, and most studies used their private dataset, leading to significant variability in data sources and formats. Annotation methodologies differed across studies, with minimal shared guidelines or standards, making direct comparisons challenging. Performance metrics varied across syndromes, with F1-score, precision, and recall as the most commonly reported. Key challenges included the lack of dataset uniformity, differences in annotation practices, and the absence of external validation. Conclusion NLP has shown potential in GS analysis, particularly for the detection of syndromes and epidemiological research. However, the majority of studies only focused on one syndrome, and variability in dataset availability, annotation processes, and model performance present challenges to broader implementation. Future research should focus on improving the comprehensiveness of GS identification, dataset standardisation, enhancing model generalisability, and integrating NLP approaches into clinical workflows.